GS-1101

DRUG2 trials

Sponsors

Gilead Sciences, Dana-Farber Cancer Institute

Conditions

Chronic Lymphocytic LeukemiaWaldenstrom's Macroglobulinemia

Phase 2

A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia

WithdrawnNCT01659047

Gilead SciencesChronic Lymphocytic Leukemia

Start: 2012-08-31End: 2015-12-31Updated: 2012-09-07

Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia

TerminatedNCT02439138

Dana-Farber Cancer InstituteWaldenstrom's Macroglobulinemia

Start: 2015-10-31End: 2016-04-30Updated: 2017-01-11